Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

US10617691B2 · kind B2 · utility

Assignee

• MORPHOSYS AG · DE

Inventors

• Jan Endell · Munich, DE
• Rainer Boxhammer · Aying, DE
• Mark Winderlich · Munich, DE

Key dates

• Filing date: May 25, 2016
• Grant date: Apr 14, 2020
• Expiry date: Jul 5, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a Bruton's tyrosine kinase (BTK) inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.